Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y, Nagasaka K, Oda K, Makii C, Takeuchi M, Oki S, Honjo H, Kojima M, Miyagawa Y, Taguchi A, Tanikawa M, Sone K, Hiraike H, Matsumoto Y, Wada-Hiraike O, Ayabe T, Osuga Y, Fujii T. Kawata Y, et al. Among authors: makii c. Cancer Sci. 2020 Oct;111(10):3824-3834. doi: 10.1111/cas.14583. Epub 2020 Aug 7. Cancer Sci. 2020. PMID: 32713096 Free PMC article.
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Makii C, Ikeda Y, Oda K, Uehara Y, Nishijima A, Koso T, Kawata Y, Kashiyama T, Miyasaka A, Sone K, Tanikawa M, Tsuruga T, Mori-Uchino M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Kawana K, Hasegawa K, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Makii C, et al. Gynecol Oncol. 2019 Nov;155(2):331-339. doi: 10.1016/j.ygyno.2019.08.028. Epub 2019 Sep 5. Gynecol Oncol. 2019. PMID: 31493899
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Makii C, et al. Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175. Oncotarget. 2016. PMID: 27659536 Free PMC article.
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T. Inaba K, et al. Among authors: makii c. Oncotarget. 2016 May 17;7(20):29577-91. doi: 10.18632/oncotarget.8807. Oncotarget. 2016. PMID: 27102436 Free PMC article.
Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.
Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, Miyasaka A, Kashiyama T, Arimoto T, Kuramoto H, Kawana K, Yano T, Osuga Y, Fujii T. Chuwa AH, et al. Among authors: makii c. Gynecol Oncol. 2016 Jun;141(3):564-569. doi: 10.1016/j.ygyno.2016.04.003. Epub 2016 Apr 16. Gynecol Oncol. 2016. PMID: 27079211
Putative tumor suppression function of SIRT6 in endometrial cancer.
Fukuda T, Wada-Hiraike O, Oda K, Tanikawa M, Makii C, Inaba K, Miyasaka A, Miyamoto Y, Yano T, Maeda D, Sasaki T, Kawana K, Fukayama M, Osuga Y, Fujii T. Fukuda T, et al. Among authors: makii c. FEBS Lett. 2015 Aug 4;589(17):2274-81. doi: 10.1016/j.febslet.2015.06.043. Epub 2015 Jul 13. FEBS Lett. 2015. PMID: 26183563 Free article.
Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas.
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H. Uehara Y, et al. Among authors: makii c. PLoS One. 2015 Jul 6;10(7):e0132751. doi: 10.1371/journal.pone.0132751. eCollection 2015. PLoS One. 2015. PMID: 26147301 Free PMC article. No abstract available.
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H. Uehara Y, et al. Among authors: makii c. PLoS One. 2015 Jun 4;10(6):e0128066. doi: 10.1371/journal.pone.0128066. eCollection 2015. PLoS One. 2015. PMID: 26043110 Free PMC article.
12 results